Skip to main content
. 2020 Nov 6;27(9):1371–1378. doi: 10.1093/ibd/izaa283

TABLE 2.

Adverse Events by Body Site

Body System N = 49
% (n)
Gastrointestinal
Diarrhea 44.9% (22)
Rectal Bleeding 16.3% (8)
Abdominal Painc, d 26.5 (13)
Nausea 10.2% (5)
Vomiting 6.1% (3)
Heart Burn 4.1% (2)
Constipation 2% (1)
Rectal Abscess 2% (1)
Right lower Quadrant Pain 2% (1)
Gastritis 2% (1)
Bloating 2% (1)
Discoloured Stool 2% (1)
IBD flarea 2% (1)
Systemic
Fever 10.2% (5)
Fatigue 6.1% (3)
Chills 4.1% (2)
Night sweats 2% (1)
Anemiab 2% (1)
Burning pain on feet 2% (1)
Pedal bilateral edema 2% (1)
Respiratory
Cough 2% (1)
Dermatologic
Shingles 2% (1)
Eczema 2% (1)
Cyst 2% (1)
Swollen lymph nodes 2% (1)
Rash 2% (1)
Polymorphous light eruption 2% (1)
Skin abscess 2% (1)
Neurological
Migraine 4.1% (2)
Genitourinary
Yeast infection 4.1% (2)
Kidney stones 2% (1)
Musculoskeletal
Muscle soreness 2% (1)
Back pain 2% (1)
Infection
Oral infection 2% (1)
Pharyngitis 2% (1)

aGrade 3 IBD flare that resulted in a hospitalization in 1 subject reported during the week 8 follow-up. Subject was treated with Remicade and discharged from hospital.

bSubject with anemia required blood transfusions and reported the event during their week 8 follow-up. The event was deemed to be disease-related not treatment-related; it was resolved with transfusion.

cSubject went to ER for general GI pain and reported the event during their week 26 follow-up. Subject was given Percocet to take as needed.

dOne subject visited the ER due to abdominal pain and reported this event during their week-12 visit. Subject was treated with pain medication.